scispace - formally typeset
Search or ask a question

Showing papers by "N. Franklin Adkinson published in 1980"


Journal ArticleDOI
TL;DR: Under the conditions of this study, the current standard method of immunotherapy produced a significant decrease in ragweed hay fever symptom-medication scores, increase in antiragweed IgG levels, and decrease in seasonal rise in antigweed IgE levels in comparison with the effects of either Rinkel method or placebo.
Abstract: In a double-blind study, we compared the effects of the Rinkel and the current standard methods of immunotherapy with ragweed pollen extract and those of placebo on symptoms of ragweed hay fever and immunologic parameters in 43 patients highly sensitive to ragweed. Each had a skin-test end point by Rinkel serial titration at 1:312,500 w/v or greater dilution, a 2+ skin test to ragweed AgE 0.01 μg/ml, and in vitro histamine release by ragweed pollen extract. None had had immunotherapy for at least 7 yr. Patients were matched on the basis of leukocyte histamine release to ragweed pollen extract and assigned to treatment groups. Fourteen received ragweed pollen extract by the Rinkel method, 14 received placebo, and 15 received ragweed pollen extract by the current standard method weekly between February and October, 1979. Rinkel method doses were derived from skin-test end points and were advanced to 0.5 ml of the end-point dilution; current standard method doses were advanced to the highest tolerated dose. The median maintenance dose for Rinkel method patients was 0.5 ml of 1:1,562,500 w/v (0.001 μg AgE), and for current standard method patients was 0.3 ml of 1:100 w/v (11 μg AgE). An additional unmatched group of nine similar patients received Rinkel method immunotherapy in both 1978 and 1979. Under the conditions of this study, the current standard method of immunotherapy produced a significant decrease in ragweed hay fever symptom-medication scores, increase in antiragweed IgG levels, and decrease in seasonal rise in antiragweed IgE levels in comparison with the effects of either Rinkel method or placebo. The effect of the Rinkel method on these variates was not significantly different from the effects of placebo.

105 citations


Journal ArticleDOI
TL;DR: Rinkel method immunotherapy with ragweed pollen extract was no more effective than placebo given in an imitation of the Rinkel method, and despite the absence of specific effect on symptom-medication scores and measured immunologic variates, 10 of the 12 ragweed-treated patients were of the opinion that their hay fever symptoms during the rag weed pollen season were less severe in 1978 than in 1977 and that they had been helped by Rinkel process immunotherapy.
Abstract: In a double-blind study, we compared the effects of the Rinkel method of immunotherapy with ragweed pollen extract and placebo on symptoms of ragweed hay fever and immunologic parameters in 24 ragweed-sensitive patients. Each had a skin-test end point by Rinkel serial dilution titration to ragweed pollen extract at 1:312,500 w/v or greater dilution, a 2 + skin test to ragweed AgE at 0.1 microgram /ml or greater dilution, and in vitro leukocyte histamine release by ragweed pollen extract. None had had immunotherapy for at least 7 yr. Patients matched on the basis of leukocyte histamine release by ragweed were assigned to two treatment groups (12 patients in each group). One group received ragweed pollen extract, and the other, placebo, both administered by the Rinkel method between June and October, 1978. Treatment doses were derived from skin-test end points. The median maintenance ("optimal dose") for patients receiving ragweed pollen extract was 0.53 ml of 1:312,500 w/v and the mean cumulative dose of ragweed pollen extract given during the study contained 0.094 micrograms of ragweed AgE. Symptom-medication scores of all patients rose and fell with ragweed pollen counts. No significant differences were observed in mean daily symptom-medication scores, antiragweed IgG or IgE levels, leukocyte histamine release by ragweed, total IgE levels, or skin-test end-point dilutions with ragweed pollen extract between the group receiving ragweed pollen extract and the group receiving placebo. Despite the absence of specific effect on symptom-medication scores and measured immunologic variates, 10 3f the 12 ragweed-treated patients and 10 of the 12 placebo-treated patients were of the opinion that their hay fever symptoms during the ragweed pollen season were less severe in 1978 than in 1977 and that they had been helped by Rinkel method immunotherapy. Under the conditions of the study, Rinkel method immunotherapy with ragweed pollen extract was no more effective than placebo given in an imitation of the Rinkel method.

91 citations



Journal ArticleDOI
TL;DR: The results indicate that the immunologic properties of UDE in humans are similar to those in mice, and the clinical applicability of these properties remains doubtful.
Abstract: Urea-denatured antigen E (UDE) has lost the major determinants of antigen E (AgE), eliciting neither IgE nor IgG antibodies to native AgE in mice. UDE, however, stimulates T cells so that repeated injections result in specific but partial suppression of ongoing IgE responses to native AgE. An attempt was made to apply this property to the treatment of 10 ragweed-allergic human volunteers by repeated subcutaneous injections of UDE over about 18 mo. Local and systemic allergic reactions limited the dose to 4 to 75 μg UDE per injection. Little or no antibody response to AgE was induced. Five patients had increased basophil sensitivity to UDE after 4 mo of injections. Five of eight patients who completed the study had evidence of suppression of IgE responses by exhibiting a 20% or less increase of IgE antibodies to ragweed on natural seasonal exposure. Three patients still exhibited this evidence at the next season of exposure 10 mo after the last injection. The two patients who received the lowest doses had greater than usual seasonal rises of IgE antibodies. There was no clinical evidence of improvement of hay fever symptoms. The results indicate that the immunologic properties of UDE in humans are similar to those in mice. The clinical applicability of these properties remains doubtful.

14 citations